Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Atopic Dermatitis - Drug Pipeline Insight, 2026 | 100+ Companies and 120+ Therapies Fuel Biologics, TYK2 Inhibitors, Licensing, and Investment Opportunities

globenewswire.com
VNDA Vanda Pharmaceuticals is mentioned as one of the companies covered in a report on Atopic Dermatitis pipeline insights. The article does not provide specific details on their pipeline or performance, thus the sentiment is neutral. APOG Apogee Therapeutics is mentioned as having a Phase II candidate (APG777) for Atopic Dermatitis. The article provides no further details on the drug's progress or the company's outlook, resulting in a neutral sentiment. BCRX BioCryst Pharmaceuticals is listed as a company covered in the Atopic Dermatitis pipeline report, with a Phase I candidate (STAR-0310). The article does not offer specific performance data or outlook for the company, leading to a neutral sentiment. CELH Celldex Therapeutics is mentioned as one of the companies covered in the Atopic Dermatitis pipeline report. No specific details about their products or performance are provided, hence the sentiment is neutral.

Atopic Dermatitis - Drug Pipeline Insight, 2026 | 100+ Companies and 120+ Therapies Fuel Biologics, TYK2 Inhibitors, Licensing, and Investment Opportunities Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Atopic Dermatitis - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.

This report provides a comprehensive analysis of the global Atopic Dermatitis pipeline, covering 100+ companies and 120+ investigational drugs across clinical and nonclinical development. It evaluates pipeline products by development stage, product type, route of administration and molecule type, while also examining discontinued and inactive candidates.

Atopic Dermatitis Overview

Atopic Dermatitis (AD), also called eczema, is a chronic inflammatory skin condition that commonly begins in childhood but may occur at any age. It can be recurrent or persistent, with symptoms that include dry skin, intense itching, redness, rash, discoloration and lichenification. Moderate-to-severe Atopic Dermatitis is frequently associated with asthma, allergic rhinitis and food allergies.

The pathophysiology of Atopic Dermatitis is complex and multifactorial, involving skin barrier dysfunction, altered cell-mediated immune responses, IgE-mediated hypersensitivity, genetic susceptibility and environmental factors. Loss-of-function mutations in filaggrin have been associated with severe disease through increased trans-epidermal water loss, altered pH and dehydration. Dysregulation of Th2 and Th1 cytokine activity may also promote immune abnormalities and hypersensitivity. Langerhans cells, inflammatory dendritic epidermal cells and plasmacytoid dendritic cells contribute to disease development.

Diagnosis generally includes a detailed medical history, assessment of allergies and associated conditions, identification of possible triggers, review of previous treatments and examination of affected skin. Blood testing or skin biopsy may be used to exclude alternative causes. Treatment strategies are tailored to disease severity, rash location, individual triggers and therapeutic response. Current options include moisturizers, corticosteroids, calcineurin inhibitors and biologics, with the goals of reducing inflammation and itching, restoring the skin barrier, preventing infection and limiting flare-ups.

Atopic Dermatitis Pipeline Analysis

The report reviews the current Atopic Dermatitis treatment landscape and future market opportunities through detailed clinical and commercial assessments. Pipeline drug profiles include mechanisms of action, clinical studies, regulatory approvals where applicable, development technologies, collaborations, licensing agreements, mergers and acquisitions, funding activities and regulatory designations.

Companies and academic institutions are investigating novel therapeutic approaches intended to address persistent unmet needs in Atopic Dermatitis treatment. The analysis covers Phase III, Phase II, Phase I, Preclinical and Discovery programs, along with relevant clinical trial updates, pharmacological activity, agreements, collaborations and product development news.

Selected Emerging Atopic Dermatitis Drugs

Therapeutic Assessment and Development Activity

The Atopic Dermatitis pipeline is segmented by clinical stage, including late-stage Phase III products, mid-stage Phase II candidates, early-stage Phase I programs, Pre-clinical and Discovery assets, and discontinued or inactive candidates. Innocare Pharma is among the companies with an Atopic Dermatitis candidate in Phase III development.

Routes of administration assessed in the report include oral, intravenous, subcutaneous, parenteral and topical delivery. Molecule types include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers and gene therapies. Products are also classified as Mono, Combination or Mono/Combination therapies.

The report evaluates collaborations, Industry-Industry and Industry-Academia partnerships, licensing transactions, acquisitions, mergers and other strategic activities shaping Atopic Dermatitis research and development. It also examines clinical trial status, emerging technologies, drug classes, regulatory designations, unmet needs and the potential impact of investigational treatments.

Key Companies and Products

Companies covered include Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics and BioCryst Pharmaceuticals.

Selected pipeline products include Tradipitant, TDM 180935, ASN002, AX 158, Soquelitinib, YH 35324, BV-200, RLS 1496, ICP-332, APG777, Barzolvolimab, ATI-2138 and STAR-0310. Together, these programs illustrate the range of mechanisms, molecule types and development strategies being explored across the Atopic Dermatitis therapeutics market.

Key Topics Covered:

Introduction

Executive Summary

Atopic Dermatitis: Overview

Pipeline Therapeutics

Therapeutic Assessment

Atopic Dermatitis- Analytical Perspective

Late Stage Products (Phase III)

ICP-332: Innocare Pharma

Mid Stage Products (Phase II)

APG777: Apogee Therapeutics

Early Stage Products (Phase I)

STAR-0310: BioCryst Pharmaceuticals

Preclinical and Discovery Stage Products

Inactive Products

Atopic Dermatitis Key Companies

Atopic Dermatitis Key Products

Atopic Dermatitis- Unmet Needs

Atopic Dermatitis- Market Drivers and Barriers

Atopic Dermatitis- Future Perspectives and Conclusion

Atopic Dermatitis Analyst Views

Appendix

List of Tables [12]

List of Figures [12]

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/f8nwqi

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.